Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The treatment of 34 patients with secondary aldosteronism with a new oral and parenteral preparation (Osyrol) is reported. On the strength of the clinical results with remissions of signs of heart failure and increase in the volume of urine, reduction of body weight and raising of serum potassium, the efficacy of the preparation with good general and local tolerance is described.
 ...
PMID:[Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)]. 81 Jun 73

Nineteen ambulant patients in cardiac insufficiency stages III to IV, eleven of them concomitantly presenting hypertension, were treated with Osyrol 50-Lasix for a period of three months. With a maintenance dose consisting on average of one capsule Osyrol 50-Lasix daily, effective and reliable elimination of edema and adequate recompensation of the heart was achieved by way of reduction of the body weight, decrease in ankle circumference, congestion of the liver and improvement of dyspnoea. In the eleven patients with hypertension grade I, the systolic and diastolic blood pressure was normalized under Osyrol 50-Lasix medication, whilst the blood pressure values of normotensive patients were practically unchanged. The serum potassium values at the beginning of the study were 4.29 mmol/l on average and increased moderately to 4.83 mmol/l after three months' therapy. Compared to pre-trial controls the serum values of creatinine and uric acid showed no changes attributable to the drug after three months' therapy with Osryol 50-Lasix. No significant change of the fasting blood glucose values was ascertained either in the nondiabetic or in the diabetic patients. Based on the clinical and laboratory-chemical parameters the success of therapy was considered to be good in 18 patients and satisfactory in one case. Tolerability was also considered to be good in 18 cases. Transient side effects were observed in two patients. Hypotension was diagnosed in one case after four weeks' treatment and in a further patient an increased serum potassium level was found. After reducing the dose the values reverted to normal in both cases.
 ...
PMID:[Long term experiences with a solid spironolactone-furosemide combination in heart insufficiency and hypertension]. 680 28

In 14 elderly male residents of a veterans' care complex who were receiving diuretic therapy for cardiac failure, oral potassium (K) supplements were withdrawn. Plasma and erythrocyte K levels were measured immediately before and six weeks after withdrawal of the supplements (38 mEq K daily). The controls comprised 19 elderly residents without disease and not taking drugs likely to influence K status. Study subjects and controls were receiving the same diet (average daily K content 100 mEq). After withdrawal of K supplements, the mean plasma K level fell significantly but the mean erythrocyte K level remained unchanged and did not differ from the control values. For a further six weeks after the withdrawal period, 7 subjects were treated with Aldactazide (diuretic hydrochlorothiazide plus K-sparing spironolactone). The plasma K level increased significantly but the erythrocyte K level remained unchanged. It was concluded that, in this setting, diuretic-induced hypokalemia is not necessarily accompanied by intracellular K depletion and that routine prophylaxis with K supplements or K-sparing agents is unnecessary and not without risk. Such therapy should be reserved for patients considered at special risk of K depletion because of known poor dietary intake, advanced liver disease, secondary hyperaldosteronism with renovascular hypertension, gastrointestinal losses, or nondiuretic medication known to affect K status adversely.
 ...
PMID:Diuretics and the institutional elderly: a case against routine potassium prescribing. 720 9